GENFIT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.21 EUR | +1.58% |
|
+1.58% | -9.32% |
Chart calendar GENFIT
3c6745b790.aUrlX6RO-zyFi4QmpWYqYLJfUlfh-Cd0pFwBwWEx-1w.ESmyEJ0jv0ncwdwSwzJbMcUqHi-0rUwlx2sy8CdHvzomJb8SlHyZWeLytA~dfaee3dc011f500a5086d6bdb4b39d67
Upcoming events on GENFIT
Past events on GENFIT
| 05/04/2024 01:40 am | Q4 2023 Earnings Release |
| 29/02/2024 | Q4 2023 Sales and Revenue Release |
| 07/02/2024 11:00 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 14/11/2023 08:30 pm | American Association for the Study of Liver Diseases Conference - Dr. Christopher Bowlus |
| 14/11/2023 03:15 am | American Association for the Study of Liver Diseases Conference - Abstract No - #484 |
| 14/11/2023 12:00 am | American Association for the Study of Liver Diseases Conference - Dr. Stephen Harrison |
| 13/11/2023 05:00 am | American Association for the Study of Liver Diseases Conference |
| 11/11/2023 11:00 pm | American Association for the Study of Liver Diseases Conference - Dr. Jennifer Lai |
| 10/11/2023 | American Association for the Study of Liver Diseases Conference - Poster No - #2082 |
| 10/11/2023 | American Association for the Study of Liver Diseases Conference - Poster No - #2100 |
| 10/11/2023 | American Association for the Study of Liver Diseases Conference - Oral Presentation No - #238 |
| 10/11/2023 | American Association for the Study of Liver Diseases Conference - Poster No - #2089 |
| 10/11/2023 02:40 am | Q3 2023 Sales and Revenue Release |
| 24/10/2023 | HealthTech Innovation Day |
| 09/10/2023 | Investor Access Conference |
| 04/10/2023 | Portzamparc BNP Paribas Biotech & Health Seminar |
| 21/09/2023 01:45 am | Q2 2023 Earnings Call |
| 21/09/2023 01:40 am | Q2 2023 Earnings Release |
| 12/09/2023 07:00 pm | H.C. Wainwright Global Investment Conference |
| 11/09/2023 | Morgan Stanley Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 41,0 21,3 92.46% | 7,76 8,30 -6.55% | 85,6 30,6 179.69% | 26,6 17,4 53% | 38,2 61,6 -38.07% | 89,6 |
|
EBITDA Million EUR | Released Forecast Spread | -52,4 -72,5 27.64% | -74,0 -70,7 -4.77% | 34,6 -60,4 157.19% | -25,5 -35,6 28.55% | -24,9 -38,2 34.76% | 29,9 |
|
EBIT Million EUR | Released Forecast Spread | -57,8 -81,9 29.42% | -77,6 -75,9 -2.18% | 31,8 -33,9 193.83% | -27,3 -38,5 29.06% | -26,6 -25,4 -4.81% | 14,9 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -65,7 -87,1 24.57% | -102 -75,5 -34.71% | 69,5 -7,42 1035.77% | -23,8 -34,1 30.02% | -28,5 -23,2 -23.13% | 27,4 |
|
Net income Million EUR | Released Forecast Spread | -65,1 -90,4 27.93% | -101 -93,5 -8.26% | 67,3 -22,5 398.86% | -23,7 -42,5 44.21% | -28,9 -21,9 -32.17% | 15,3 |
|
EPS EUR | Released Forecast Spread | -1,76 -3,05 42.3% | -2,60 -2,08 -24.91% | 1,23 -1,56 178.94% | -0,48 -0,96 50% | -0,58 -0,56 -3.66% | 0,47 |
| Announcement Date | 08/04/20 | 01/04/21 | 07/04/22 | 13/04/23 | 04/04/24 | - |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 35,6 25,7 38.45% | 5,87 3,57 64.57% | 1,89 4,53 -58.26% | 3,43 3,88 -11.54% | 82,2 124 -33.75% | 12,2 15,6 -21.62% | 14,4 13,6 5.99% | 15,4 14,3 7.36% | 22,8 75,7 -69.87% | 44,6 | 50,8 |
|
EBIT Million EUR | Released Forecast Spread | -11,9 -29,2 59.27% | -49,2 -44,2 -11.14% | -28,4 -38,4 25.88% | -29,6 -33,2 11.06% | 61,4 89,0 -31.03% | -14,3 -31,4 54.35% | -12,9 -27,9 53.6% | -19,3 -24,3 20.51% | -7,28 10,1 -172.3% | 15,2 | 11,2 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -14,3 -29,9 52.21% | -53,2 -45,9 -15.75% | -48,5 -41,2 -17.81% | 6,16 -36,3 116.97% | 63,3 86,6 -26.87% | -10,4 -32,4 68.05% | -13,5 -28,9 53.37% | -20,4 -24,8 17.51% | -8,07 9,87 -181.8% | 15,7 | 11,7 |
|
Net income Million EUR | Released Forecast Spread | -14,0 -29,8 53.01% | -53,0 -45,8 -15.79% | -48,2 -41,2 -17.16% | 9,06 -36,3 124.94% | 58,2 86,6 -32.77% | -10,4 -22,0 52.65% | -13,3 -41,4 67.83% | -20,9 -16,7 -25.22% | -8,04 9,87 -181.46% | 10,8 | 15,6 |
|
EPS EUR | Released Forecast Spread | -0,12 -1,37 91.24% | -0,42 -0,20 -110% | |||||||||
| Announcement Date | 08/04/20 | 30/09/20 | 01/04/21 | 29/09/21 | 07/04/22 | 28/09/22 | 13/04/23 | 20/09/23 | 04/04/24 | - | - |
More events
Past sector events for GENFIT
| Today | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| Today | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 26/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 04:30 pm | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 11:30 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GNFT Stock
- Calendar GENFIT
